Drug intelligence / Profile preview

BMS-986207 + nivolumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BMS-986207 + nivolumab is a combination of two investigational and approved monoclonal antibodies being studied for the treatment of advanced solid tumors. BMS-986207 is an anti-TIGIT antibody that targets TIGIT, an inhibitory receptor on T cells and natural killer (NK) cells, aiming to enhance immune activation against tumors. Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor approved for several cancers, blocking the PD-1 pathway to restore T-cell function. This combination is being developed and investigated by Bristol-Myers Squibb as an immunotherapy regimen to enhance anti-tumor immune responses in patients with advanced solid or metastatic tumors[1][4][7].

Other names: anti-TIGIT antibody + anti-PD-1 antibody

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BMS-986207 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986207 + nivolumab.

Explore the full profile